{"id":"d3d3ff96-9b10-534e-bac9-c689fe8b704b","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:mouse-shikimic-acid-oral-exposure","predicate":"reported_relationship","statement":"Estimated oral shikimic-acid bioavailability was approximately 11.09–20.44% in the tested mice.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"185da8a4-b180-5e9a-b3de-daae340aa33b","mechanism_event_label":"Estimated oral shikimic-acid bioavailability was approximately 11.09–20.44% in the tested mice.","subject":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"object":{"id":"ab6df0c9-2ebe-532d-863a-d947b1fa530f","slug":"mouse-shikimic-acid-oral-exposure","display_name":"Mouse oral shikimic-acid exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"185da8a4-b180-5e9a-b3de-daae340aa33b","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:mouse-shikimic-acid-oral-exposure-event","event_type":"experimental_observation","label":"Estimated oral shikimic-acid bioavailability was approximately 11.09–20.44% in the tested mice.","description":"**Mouse distribution and bounded toxicity observations.** The 2025 mouse study reported intravenous half-lives approximately 0.76–0.85 h at 4–16 mg/kg and oral bioavailability approximately 11.09–20.44% at 50–100 mg/kg. A short plasma half-life does not prove unchanged renal excretion. In a separate 28-day feeding experiment, dietary concentrations were 5.56, 16.67 and 50 g/kg FEED, not mg/kg body weight. High-dose animals had small hematological shifts and lower triglycerides; acute survival through tested doses is not evidence of lifetime human safety. No validated human monocarboxylate-transporter assignment was found in the reviewed sources. [Pharmacokinetic Profile and Evaluation of Acute and Subchronic Oral Toxicity of Shikimic Acid in Mice.](https://pubmed.ncbi.nlm.nih.gov/40852254/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"ab6df0c9-2ebe-532d-863a-d947b1fa530f","slug":"mouse-shikimic-acid-oral-exposure","display_name":"Mouse oral shikimic-acid exposure","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Mouse oral 50–100 mg/kg versus intravenous reference arms.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Species/route-specific pharmacokinetic estimate, not human exposure. Rat nominal-dose arithmetic caveat and complete time parameters remain in the source passage.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Estimated oral shikimic-acid bioavailability was approximately 11.09–20.44% in the tested mice.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Pharmacokinetic Profile and Evaluation of Acute and Subchronic Oral Toxicity of Shikimic Acid in Mice. | 2025 | DOI 10.1021/acsomega.5c03740 | PMID 40852254 | https://pubmed.ncbi.nlm.nih.gov/40852254/ | https://doi.org/10.1021/acsomega.5c03740 | https://pmc.ncbi.nlm.nih.gov/articles/PMC12368620/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 51-51; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"e53f95b0-3091-5b64-8ad3-fada7720b6db","evidence_kind":"source_excerpt","locator":"Lines 51-51","start_line":51,"end_line":51,"excerpt":"**Mouse distribution and bounded toxicity observations.** The 2025 mouse study reported intravenous half-lives approximately 0.76–0.85 h at 4–16 mg/kg and oral bioavailability approximately 11.09–20.44% at 50–100 mg/kg. A short plasma half-life does not prove unchanged renal excretion. In a separate 28-day feeding experiment, dietary concentrations were 5.56, 16.67 and 50 g/kg FEED, not mg/kg body weight. High-dose animals had small hematological shifts and lower triglycerides; acute survival through tested doses is not evidence of lifetime human safety. No validated human monocarboxylate-transporter assignment was found in the reviewed sources. [Pharmacokinetic Profile and Evaluation of Acute and Subchronic Oral Toxicity of Shikimic Acid in Mice.](https://pubmed.ncbi.nlm.nih.gov/40852254/)","model_system":"Mouse oral 50–100 mg/kg versus intravenous reference arms.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e6ae59de-0369-5c2f-8262-57d91302671c","stable_key":"import-31b1baa4-4113-5541-b9e7-fe44a5253a07","title":"Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"95b1f9e9577661312d67f36e156d2e49326b207f296c1c0e801a5b007fd8e283","revision_id":"cd3237f1-131a-557d-84b5-7543259807b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}